A Meta-Analysis Of Efficacy And Safety Of The Monosialoganglioside GM1in Parkinson’s Disease

Objective:To evaluate the clinical efficacy and safety of the monosialoganglioside GM1(GM1) in Parkinson’s disease (PD) in the method of meta-analysis.Methods:we searched the electronic database of Cochrane Library, PubMed (1968-2014.3),-EMBASE (1976-2014.3), web of science (1960-2014.3), the Chinese WangFang Literature Database (1994-2014.3), Weipu Information Network (1991-2014.3), China National Knowledge Infrastructure(1996-2014.3), the Chinese Biomedical Literature (1980-2014.3). The Review Manager5.2software was used to Meta-analysis and using Cochrane Collaboration systematic review methods to access the quality of these studies.A fixed-effect model or random-effect model based on the heterogeneity test were used to analyze data.Results:Two studies involving125cases were included. The results of Meta-analysis showed that the improvement of motor score in Unified Parkinson’s Disease Rating Scale(UPDRS) between GM1group and placebo group,the risk of causing injection site-related adverse reactions in GM1group versus placebo group,both of which are statistically significant differences.Conclusions:GM1is effective to improve the motor function in patients with PD,and the adverse reations are mild in the cause of treatment. In addition, the results of our study was uncertainty because the number of the included study was few and the defect their self. We need more multi-center, randomized, double-blind experiments to confirm these conclusions further.